



## **Inari Medical to Announce Fourth Quarter and Full-Year 2021 Financial Results**

February 10, 2022

IRVINE, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) ("Inari"), a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced today that it will release its fourth quarter and full-year financial results on Wednesday, February 23, 2022. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

Interested parties may access the live call via telephone by dialing (833) 519-1265 for domestic callers or (914) 800-3838 for international callers, using conference ID: 3126888. The live webinar may be accessed by visiting the Events Section of the Inari investor relations website at [ir.inarimedical.com](http://ir.inarimedical.com). A replay of the webinar will be available shortly after the conclusion of the call and will be archived on Inari's website.

### **About Inari Medical, Inc.**

Inari Medical, Inc. is a medical device company focused on developing innovative products to treat and transform the lives of patients suffering from venous diseases. Inari has developed two minimally invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs. The company purpose-built its products for the specific characteristics of the venous system and the treatment of the two distinct manifestations of venous thromboembolism, or VTE: deep vein thrombosis and pulmonary embolism. The ClotTrieve system is 510(k)-cleared by FDA and CE marked for the non-surgical removal of clot from peripheral blood vessels, including for the use in the treatment of deep vein thrombosis. The FlowTrieve system is 510(k)-cleared by FDA and CE marked for the non-surgical removal of clot from peripheral blood vessels, including for the use in the treatment of pulmonary embolism and clot in transit in the right atrium.

### **Investor Contact:**

Westwicke Partners  
Caroline Corner  
Phone +1-415-202-5678  
[caroline.corner@westwicke.com](mailto:caroline.corner@westwicke.com)